Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891792 | 0.81 | ABL1 (0.72) | MEN1KMT2AALDH1A1ABL1GSTO1 | |
| SCHEMBL2901322 | 0.79 | MEN1 (0.60) | MEN1KMT2AALDH1A1ABL1GSTO1 | |
| SCHEMBL10808572 | 0.79 | MEN1 (0.82) | MEN1KMT2AALDH1A1ABL1GSTO1 | |
| SCHEMBL10924496 | 0.79 | ABL1 (0.78) | MEN1KMT2AALDH1A1ABL1GSTO1 | |
| SCHEMBL10954503 | 0.78 | MAPT (0.61) | MEN1KMT2AALDH1A1GSTO1MAPT | |
| SCHEMBL4089149 | 0.78 | ABL1 (0.72) | MEN1KMT2AALDH1A1ABL1GSTO1 | |
| SCHEMBL6249035 | 0.78 | SCD (0.74) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL17107148 | 0.77 | SCD (0.78) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL2754064 | 0.77 | ROCK2 (0.62) | MEN1KMT2AALDH1A1GSTO1MAPT | |
| SCHEMBL5184586 | 0.77 | GSTO1 (0.57) | MEN1KMT2AALDH1A1GSTO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | claimed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | claimed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | claimed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | MEN1 2826/4885KMT2A 2486/4885ALDH1A1 3196/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | MEN1 4490/4885KMT2A 4046/4885ALDH1A1 863/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | MEN1 2786/4885KMT2A 2406/4885ALDH1A1 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.